Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jbio.202380001 | DOI Listing |
J Sleep Res
December 2024
Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
This study explored the prospective associations between sleep patterns, mental health and registry-based school grades among older adolescents. In the spring of 2019, 1st year high-school students in Western Norway were invited to a survey assessing habitual sleep duration, insomnia, depression and anxiety. Sleep patterns, depression and anxiety were assessed using the Munich ChronoType Questionnaire, the Bergen Insomnia Scale, the Patient Health Questionnaire-9, and the Generalized Anxiety Disorder-7.
View Article and Find Full Text PDFBMC Psychiatry
November 2024
Department of Health, Society, and Behavior, Joe C. Wen School of Population & Public Health, University of California, Irvine, 856 Health Sciences Quad, Irvine, CA, 92697-3957, USA.
Microbiology (Reading)
November 2024
Agriculture and Agri-Food Canada, Lethbridge Research and Development Centre, 5403 - 1st Avenue South, Lethbridge, Alberta, T1J 4B1, Canada.
Grasslands are estimated to cover about 40% of the earth's land area and are primarily used for grazing. Despite their importance globally, there is a paucity of information on long-term grazing effects on the soil microbiome. We used a 68-year-old grazing experiment to determine differences in the soil permanganate-oxidizable C (POXC), microbial biomass C (MBC), the soil prokaryotic (bacterial and archaeal) community composition and enzyme activities between no-grazing, light grazing and heavy grazing, i.
View Article and Find Full Text PDFClin Cancer Res
October 2024
United States Food and Drug Administration, Silver Spring, MD, United States.
On December 1st, 2022, the FDA approved the new molecular entity olutasidenib (Rezlidhia: Rigel Pharmaceuticals), a small-molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. The efficacy of olutasidenib was established based on complete remission (CR) + CR with partial hematological recovery (CRh) rate, duration of CR + CRh, and conversion of transfusion dependence (TD) to transfusion independence (TI) in Study 2102-HEM-101. In the pivotal trial, 147 adult patients treated with 150mg twice daily (BID) of olutasidenib were evaluable for efficacy.
View Article and Find Full Text PDFPlant Dis
October 2024
USDA-ARS, Dept. of Plant Pathology, University of California, One Shields Av, Davis, California, United States, 95616;
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!